NCT02949700View on ClinicalTrials.gov

Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

January 26, 2017

Primary Completion Date

June 28, 2021

Study Completion Date

July 7, 2022

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

Metformin

Metformin will be administered orally twice daily during treatment with chemo-radiation for head and neck squamous cell carcinoma. This will occur 7 to 11 days prior to chemotherapy and radiation.

Trial Locations (3)

77030

Baylor College of Medicine, Houston

Michael E. DeBakey Veterans Affairs Medical Center, Houston

77054

Harris Health System - Smith Clinic, Houston

All Listed Sponsors
lead

Baylor College of Medicine

OTHER

NCT02949700 - Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter